Skip to main content

Successfully unsubscribed from ETtech Unwrapped

The Economic Times

Dear Reader,

As per your request, you have been removed from our mailing list for ETtech Unwrapped

Get all the updates from the world of business straight to your inbox

Getting bigger and stronger. 4 million+ subscribers

 MANAGE ALL
NEWSLETTERS»
365

Daily Newsletter

Your daily dose of business news, views and updates.
SUBSCRIBE
Economy

ET Economy

Get the latest on economy, policy, insights & trends
SUBSCRIBE
ETtech Top 5

ETtech Top 5

A closer look at today's biggest tech and startup news and why they matter
SUBSCRIBE
Markets-Watch

Markets Watch

Latest stock market & business news
SUBSCRIBE
Wealth

Wealth

The week's best and important stories for all your personal finance
SUBSCRIBE
Politics and Nation

Politics and Nation

Keep up with nation's politics and development        
SUBSCRIBE
Facebook Twitter YouTube LinkedIn
About us|Advertise with us|Feedback|Sitemap|Code of Ethics
© 2024 Times Internet Limited.
To ensure delivery directly to your inbox, please add etnotifications@indiatimes.com to your address book today.

To unsubscribe or edit your subscriptions please click here

Comments

Post a Comment

Popular posts from this blog

The first drug for a common, deadly liver disease is here – and more are coming

VIEW IN BROWSER | SUBSCRIBE TUE, MAR 19, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good morning!  Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition.    In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug " Rezdiffra ," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates.    So, why is this approval so important?    First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with nonalcoholic steatoh
Post a Comment
Read More

J&J, Merck and Bristol Myers Squibb are in the hot seat

VIEW IN BROWSER | SUBSCRIBE TUE, JAN 30, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com .    Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead.    CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday.   It took subpoena threats from the senator, but J&J CEO Joaquin Duato and Merck CEO Robert Davis have agreed to testify after both executives declined earlier requests to appear at the Senate HELP committee's hearing. They join Bristol Myers Squibb CEO Chris Boerner, who agr
Post a Comment
Read More

How competitive can Roche be in the weight loss drug market?

VIEW IN BROWSER | SUBSCRIBE TUE, SEP 17, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon!  Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly?  The answer isn't clear yet.  We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct.  But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised concerns about how competitive those products can be if they enter the space. Some analysts said the new results showed that both drugs – which Roche acquired through its nearly $3 billion acquisition of Carmot Therapeutics in December – caused a higher rate of side
Post a Comment
Read More